Roche's Breast Cancer Drug Giredestrant Receives FDA Priority Review
Roche (RHHBY) announced that the U.S. Food and Drug Administration has granted priority review for its breast cancer drug giredestrant, an endocrine therapy targeting a specific subset of patients with breast cancer.
